The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle

• Status: Completed
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects with type 2 diabetes will be treated with Actos or placebo for eight weeks and needle biopsies of muscle will quantify changes in any of seven different glucose transport proteins in muscle.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: East Tennessee State University
• Collaborator: Takeda Pharmaceuticals North America, Inc.
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• diabetes, type 2

• HbA1c less than 8.5

Exclusion Criteria:

• insulin therapy

• renal insufficiency

• clinically apparent coronary disease